Indivior Pharmaceuticals, Inc 6-K, filed Jun 30, 2023
Indivior Pharmaceuticals, Inc. (INDV)
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on June 30, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: June 30, 2023
Commission File Number: 001-37835
Indivior PLC
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT INDEX
| Exhibit No. |
Description of Exhibit | |
| 99.1 | Announcement sent to the London Stock Exchange on June 30, 2023, titled “Director Declaration”. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | ||||||
| Date: June 30, 2023 | /s/ Kathryn Hudson | |||||
| Name: Kathryn Hudson | ||||||
| Title: Company Secretary | ||||||
Exhibit 99.1
Indivior PLC (the ‘Company’)
Indivior PLC confirms that Jerome Lande, Non-Executive Director, has advised that he will be appointed as a Non-Executive Director of R&Q Insurance Holdings Ltd (AIM:RQIH), subject to the satisfactory completion of due diligence checks typical for the appointment of a director of an AIM company.
This announcement is made in accordance with Listing Rule 9.6.14.
Kathryn Hudson
Company Secretary